Dramatic improvement after rituximab in a patient with paraneoplastic treatment‐refractory Morvan syndrome associated with anti‐CASPR2 antibodies. Issue 7 (10th June 2013) - Ong, E.; Viaccoz, A.; Ducray, F.; Pérol, M.; Cavillon, G.; Rogemond, V.; Honnorat, J.; Petiot, P.